May 2007

News and information from the pharmaceutical industry. In this issue: 1) Multiple Deals for Affitech 2) Pfizer's Sutent Wins European Association of Urology Support 3) Aurora Breast MRI Will Meet Surge in Screening Demand 4) Two New Products for VioQuest 5) Cytyc and Quest Sign Multi-Year Agreement 6) Calando's Lead RNAi Candidate Shows Anti-Cancer Effect

A collection of cancer statistics and facts

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery. In this issue: 1) Northwestern University: Anti-Cancer Flavonoids Synthesized 2) University of Wisconsin-Madison: Turning the Body�s Immune System on Cancer 3) The Institute of Cancer Research, Surrey, England: New Class of Anti-cancer Drugs 4) University of Utah School of Medicine: Advance Against Sarcoma 5) Duke University: Towards an Optical Biopsy 6) University of Southern California, Harvard Medical School, and National Institutes of Health: Genetic Variants Point to Prostate Cancer Risk

This month's Fed Focus highlights the CDC's HPV vaccine recommendations as well as changes in Medicare coverage of ESAs for cancer-related anemia. Our reports from "The State House" indicate that, even with the CDC's HPV vaccine recommendations, some resistance is expected at the state level.

This month we report on presentations made at the Association of Community Cancer Centers 33rd Annual National Meeting (March 28-31, 2007, Rockville, MD) and at a colorectal cancer meeting held at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (March 28-31, 2007, Baltimore, MD).

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Aveo Lands $477M Deal with Schering Plough 2) Eisai Grows Pharma-Based Cancer Pipeline in $325M Acquisition of Morphotek 3) Pharmacyclic and Genta Appeal FDA Decisions on NDAs 4) Oxford Biomedica Takes Over Oxxon Therapeutics for $31.6M 5) Micromet Could Earn $100M in Collaboration with Tracon 6) Yawkey Foundation Makes Second Largest Individual Donation to Dana-Farber $1B Campaign

The Clinical Trials reported in this issue include: PHASE I: 1) Adherex Initiates Combination Trial of ADH-1 and Melphalan for Melanoma Treatment 2) Erimos Initiates Evaluation of First-In-Class Small Molecule Therapy for Glioma Brain Tumors PHASE II: 1) ChemGenex Treats First Patient in CML Trial 2) Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase 3) Helix Shows Positive Results in Treatment of HPV-induced, Low-Grade Cervical Lesions PHASE III: 1) Amgen and ImClone's Competing EGFr-targeting Drugs Battle It Out in the Clinic

News items featured in this month's issue: 1) Preventive Health Exams May Lead to Cancer Screenings by Prachi Patel-Predd 2) Canine Cancer Vaccine Being Investigated for Use in Humans by Diane West 3) Antirejection Drug Shows Promise In Preventing Lung Cancer in Smokers by Diane West 4) Colon Cancer Survival Linked to Number of Lymph Nodes Examined by Querida Anderson 5) Combined Therapies Improve Breast Cancer Survival by Prachi Patel-Predd 6) Mapping the Cancer Genome by Nick Rose 7) Gleevec May Decrease Risk of Recurrence in Patients with Primary Gastrointestinal Stromal Tumor by John D. Zoidis, MD 8) Dendreon Closes in on Offering First Prostate Cancer Vaccine by Nick Rose 9) PSA Kinetics is a Poor Predictor of Lethal Prostate Cancer by Querida Anderson

GlaxoSmithKline's experimental cervical cancer vaccine Cervarix has proven 100% effective in preventing precancerous lesions due to cancer-causing human papillomavirus (HPV) strains 16 and 18 for up to five and a half years.

The results of Amgen's "145 study" of Aranesp in patient's with late-stage small-cell lung cancer (SCLC) are released.

With this and every issue of Oncology & Biotech News, we seek to provide clinicians with practical news with a global perspective. As we move forward, it is our goal to provide more information from markets outside the United States. Your input is essential to developing this publication into a useful tool for you in your daily practice.